2018
Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
Chong J, Oh W, Liaw B. Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. OncoTargets And Therapy 2018, 11: 2141-2147. PMID: 29695920, PMCID: PMC5905496, DOI: 10.2147/ott.s147168.Peer-Reviewed Original ResearchCastration-resistant prostate cancerMetastatic castration-resistant prostate cancerProstate cancerTreatment of metastatic castration-resistant prostate cancerM0 castration-resistant prostate cancerSecond-generation androgen receptor antagonistProstate-specific antigen responseUS Food and Drug Administration approvalFood and Drug Administration approvalMetastasis-free survivalAndrogen receptor antagonistDrug Administration approvalAndrogen-AR complexSPARTAN studyARN-509Survival benefitReceptor antagonistSymptomatic progressionAndrogen receptorRandomized studyAdministration approvalApalutamideAntigen responseTherapeutic agentsNuclear translocation
2016
Chapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer
Parihar J, Kim I. Chapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer. 2016, 533-540. DOI: 10.1016/b978-0-12-800077-9.00057-8.Peer-Reviewed Original ResearchCastrate-resistant prostate cancerProstate cancerHormonal manipulationHormone-sensitive prostate cancerSecond-line hormonal manipulationsSecond-line hormonal therapySecond-line treatment optionAssociated response ratesInitial systemic therapySecondary hormonal manipulationsSecond-generation antiandrogensFirst-generation antiandrogensAntiandrogen withdrawalARN-509Hormonal therapyMainstay treatmentAbiraterone acetateAndrogen suppressionSystemic therapyAndrogen deprivationSuch patientsTreatment optionsTherapeutic responseDisease progressionResponse rate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply